Therefore, we evaluated the clinical outcomes of primary melanoma patients treated with vaccines and immune biologics separately to determine if the observed relationship between tumor MMP-23 expression and recurrence could be attributed to an effect on a specific T cell subset (Table 4). The gene discussed is MMP23B; the disease is melanoma.